Market Overview

I think you’ll love what you hear,
what you’ll see and the opportunities
that will be set before you.
- Jon Najarian

Model N Has Happy Customers And Good Pipeline Momentum, Oppenheimer Says


Conversations with customers indicate Model N Inc’s (NYSE: MODN) products are “entrenched, difficult to replace, and considered mission-critical,” according to Oppenheimer.

The Analyst

Oppenheimer’s Koji Ikeda maintains an Outperform rating on Model N, with the price target unchanged at $23.

The Thesis

The California-based software company hosted its annual customer conference, Rainmaker19, over March 18-20. The customers expressed they were extremely satisfied with Model N’s products, Ikeda said.

The company’s products are deeply integrated within their customers’ other systems, which makes it difficult to replace them.

Managing rebates is an extremely complex process for life sciences companies, and Model N is viewed as a leader in this vertical, with limited competition to its platform capabilities.

The company has a healthy pipeline of midmarket and enterprise prospects. There were several projects with prospective revenues ranging from around $500 million to $4 billion. Ikeda noted that all these prospects were using spreadsheets, which indicates that the end-market continues to be underpenetrated.

“We think odds are favorable that the business delivers good results in future quarterly reports, which should help narrow the valuation gap between MODN and its Tier-3 SaaS peers,” the analyst wrote in the note.

Price Action

Shares of Model N traded around $17.47 Tuesday afternoon.

Related Links:

88 Biggest Movers From Yesterday

Cumberland Executives to Present Revenue Management Best Practices at Model N Rainmaker 2019

Latest Ratings for MODN

Oct 2018Initiates Coverage OnOutperform
Jul 2018Initiates Coverage OnBuy
Feb 2018UpgradesMarket PerformMarket Outperform

View More Analyst Ratings for MODN
View the Latest Analyst Ratings

Posted-In: Koji Ikeda OppenheimerAnalyst Color Analyst Ratings


Related Articles (MODN)

View Comments and Join the Discussion!

Latest Ratings

EOLSInitiates Coverage On6.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Trading Daily
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at

Cyclacel Drops After Study Supporting Cancer Drug's Mechanism Of Action

Flowhub, BDS Analytics Partner To Provide Market Insight To Dispensaries